Judith Leopold

Judith Leopold, PhD

Research Associate Professor, Radiology
Research Associate Professor, Pharmacology
Co-Director, Experimental Therapeutics Program, University of Michigan Comprehensive Cancer Center
Radiology Translational Onco Program
1600 Huron Parkway, NCRC B520-1365
Ann Arbor, MI 48109

Michigan Research Experts Profile

734-615-7326

Biography

Before joining the University of Michigan in 2009, Dr. Sebolt-Leopold was the executive director of the Mechanistic and Target Biology Department at Pfizer Global R&D in Ann Arbor, where she led a group of over 100 scientists dedicated to early stage drug discovery activities, encompassing molecular pharmacology, assay development, and biomarker validation.

Now the former Pfizer facility is the University of Michigan North Campus Research Complex, and Dr. Sebolt-Leopold is a principal investigator in TOP, where her laboratory is focused on the design of combination therapies targeting KRAS mutant cancers. Dr. Sebolt-Leopold’s team was recruited by the Center for Molecular Imaging as part of an effort to design and develop small molecules to be used for the early diagnosis of cancer. The therapeutic inhibition of protein kinases has revolutionized the treatment of certain cancers—their diversity and role in cell signaling makes them attractive targets for drug design, and the ability to non-invasively diagnose and molecularly define an individual’s tumor will enable the development of personalized therapies.

MEK is a critical component of the RAS-MAP kinase signaling pathway, which is activated in a large percentage of cancers. Dr. Sebolt-Leopold co-chaired the project team that was the first in the pharmaceutical industry to design, synthesize and advance a small molecule MEK kinase inhibitor into the clinic.

Dr. Sebolt-Leopold has led multiple cross-disciplinary research teams, resulting in the advancement of clinical candidates, including the MEK inhibitors CI-1040 and PD0325901. These agents entered the clinical arena based on their promising activity in preclinical models, where they effectively block RAS onogenic signaling.

The Sebolt-Leopold lab’s success in championing the anticancer drug potential of MEK inhibitors is reflected in the number of pharmaceutical companies subsequently launching research programs around the CI-1040/PD0325901 template. Consequently, there are nearly a dozen MEK inhibitors currently undergoing clinical evaluation.

Appointments

University of Michigan Comprehensive Cancer Center Program Director

Credentials

PhD, 1980, Purdue University